Management tracks: DBV, Beam, Aeon Biopharma
DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will not fill the deputy CEO position.
Beam Therapeutics (Cambridge, Mass.) hired Christine Bellon as SVP and chief legal officer and Suzanne Fleming as SVP of finance, and promoted Courtney Wallace to SVP and head of business development and strategy from VP. The gene editing company also hired Susan O’Connor as chief human resources officer. Bellon was SVP, general counsel of Forma Therapeutics Inc. (Watertown, Mass.). Fleming was SVP, finance at Epizyme Inc. (NASDAQ:EPZM). O’Connor was CEO of O’Connor and Associates (Cambridge, Mass.)...